<DOC>
	<DOCNO>NCT00986128</DOCNO>
	<brief_summary>The purpose study determine initial ( 1-week maintenance dose ) extend ( 3-weeks maintenance dose ) effect topiramate , dose 600 mg/day , steady-state pharmacokinetics ( absorption , distribution excretion drug body ) lithium carbonate patient bipolar disorder .</brief_summary>
	<brief_title>A Pharmacokinetic Study Lithium Before During Topiramate Dosing Bipolar Disorder Patients</brief_title>
	<detailed_description>This open-label ( investigator patient know identity study drug ) , sequential treatment , multicenter study evaluate interaction topiramate lithium patient bipolar disorder . The study population include 24 patient ( 12 patient per group ) complete data consider adequate fully evaluate extent effect topiramate lithium pharmacokinetics ( PK ) . The study consist screen phase , patient maintain stable dose immediate release lithium carbonate formulation administer every 12 hour , minimum 2 week prior start study , open-label treatment phase consist topiramate titration phase lithium topiramate maintenance phase , 3 PK sample period ( day multiple blood urine sample take estimate amount topiramate /or lithium patient blood urine ) . The duration period determine investigator . Patients sequester 48 hour 3 PK sample period . At sample period , blood urine sample collect laboratory safety analysis designate serial sample time collection interval PK sample . All dos study medication administer every 12 hour . During PK sample Period 1 , patient maintain respective morning evening dose lithium carbonate . Serial blood urine sample collect 12 hour postdose estimation lithium serum urine concentration . Patients continue lithium regimen subsequently initiate topiramate assign either low-dose Group 1 ( 200 mg/day ) high-dose Group 2 ( 600 mg/day ) . During topiramate titration phase , initial dose topiramate 25 mg/day titrate upward target dose 200 mg/day reach ( Group 1 ) target dose 600 mg/day ( maximum tolerate dose great 200 mg/day ) reach ( Group 2 ) . Topiramate dose titration conduct study Days 2 , 4 , 7 Group 1 Days 2 , 7 , 12 , 17 , 22 , 27 Group 2 . Once maximum dose topiramate reach , lithium topiramate maintenance phase begin lasted 3 week , patient maintain constant daily dose topiramate lithium carbonate . One week begin maintenance topiramate lithium carbonate , patient enter PK sample Period 2 study , serial blood urine sample collect 12 hour postdose estimation lithium serum urine concentration estimation topiramate plasma concentration . At end 3 week lithium topiramate maintenance , patient enter PK sample Period 3 study , serial blood urine sample collect 12 hour postdose estimation lithium serum urine concentration estimation topiramate plasma concentration . Throughout topiramate titration phase lithium topiramate maintenance phase , serum trough concentration lithium ( amount lithium patient blood immediately next dose ) determine prior morning dose every 3 day , begin Day 3 topiramate titration phase . Patients maintain stable dose immediate release lithium carbonate formulation 2 week prior study start . In titration phase , topiramate give every 12 hour start 25 mg/day . Patients titrate target dos 200 mg/day ( low-dose group ) period 10 day , 600 mg/day ( high-dose group ) period 30 day . The lithium topiramate maintenance phase last additional 3 week target dos reach .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Patients meet DSMIV criterion either Bipolar I , Bipolar II , Cyclothymic Disorder , Bipolar Disorder NOS Patients monotherapy treatment lithium carbonate steady state level minimum two week prior study treatment assignment Women postmenopausal least 1 year , surgically incapable childbearing , practice acceptable method birth control ( hormonal contraception , intrauterine device , barrier spermicide acceptable ) pregnant baseline Patients history acquire hereditary neurologic disease , e.g. , epilepsy significant brain trauma Patients depot medication , include limited haloperidol , decanoate DepoProvera Patients take acetazolamide , zonisamide , triamterene , dichlorphenamide , chronic antacid , calcium supplement , medication associate nephrolithiasis ( kidney stone formation ) month prior begin topiramate titration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Topiramate</keyword>
	<keyword>Lithium</keyword>
	<keyword>Bipolar disorder</keyword>
</DOC>